# Hemay

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/hemay

- Industry: Biotechnology
- Headquarters: Ganzhou, China
- Total disclosed funding: $44M
- Latest round: Series D (Feb 8, 2023)
- Investors on record: 5

## About

Based in Ganzhou, China, and founded in  2019, Hemay is a pharmaceutical company dedicated to the development of innovative medicines, with a Tianjin R&D Base, Ji'an Xiajiang Production Base, and Ganzhou Xinfeng Production Base.

The company focuses on the research and development of First In Class (FIC), Best In Class (BIC), and Only In Class (OIC) products. The products under research cover psoriasis, psoriatic arthritis, rheumatoid arthritis, specific dermatitis, chronic obstructive pneumonia, inflammatory bowel disease, ankylosing spondylitis, breast cancer, non-small cell lung cancer, solid tumors, etc.

## Funding rounds

- Series D, Feb 8, 2023, $44M — Essence Capital, Taikun Fund, Jiangxi Jianghan Investment Management, Hongfu Investment, Xinfeng County Development Control Industry Investment Fund Management

## Investors

- Essence Capital — Series D
- Taikun Fund — Series D
- Jiangxi Jianghan Investment Management — Series D
- Hongfu Investment (https://capitalatlas.ai/funds/hongfu-investment) — Series D
- Xinfeng County Development Control Industry Investment Fund Management — Series D